Scholarlink

<p>Adoptive cellular therapies have revolutionised treatment of haematological malignancies and demonstrate potential in solid tumours and autoimmune disease. Real-world implementation remains limited by biological, logistical, and manufacturing barriers, restricting global uptake despite a rapidly expanding clinical trial portfolio. Effective implementation requires national and institutional readiness, multidisciplinary collaboration, scalable manufacturing, and robust infrastructure. Efforts should prioritise decentralised and “off the shelf” platforms, integrated referral networks, and AI-assisted patient management to support safe, equitable and efficient global delivery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A roadmap for establishing institutional readiness for cellular therapies targeting solid tumours and autoimmune diseases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Sarah Childs,
  • David Ma,
  • Elizabeth Houghton,
  • Rasha Cosman,
  • Jennifer Massey,
  • Venessa Chin,
  • Valerie Valencia,
  • Aaron O’Grady,
  • Simone Kay Jensen,
  • Amanda McLaughlin,
  • Simon Goodwin,
  • Helen Tao,
  • Barbara Withers,
  • Callie Noakes,
  • Annabel Horne,
  • Paul Preisz,
  • Jessica Boyd,
  • Dion Forstner,
  • Anthony Rodrigues,
  • Geeta Sandhu,
  • Karim Ibrahim,
  • Chloe Martin,
  • Benjamin Kwan,
  • Nicolas De Luca,
  • Hergen Buscher,
  • Philip Cunningham,
  • Anthony M. Joshua,
  • Laila Girgis,
  • Ben Tran,
  • Jayesh Desai,
  • Simon J. Harrison,
  • John Moore,
  • Jia Liu

摘要

Adoptive cellular therapies have revolutionised treatment of haematological malignancies and demonstrate potential in solid tumours and autoimmune disease. Real-world implementation remains limited by biological, logistical, and manufacturing barriers, restricting global uptake despite a rapidly expanding clinical trial portfolio. Effective implementation requires national and institutional readiness, multidisciplinary collaboration, scalable manufacturing, and robust infrastructure. Efforts should prioritise decentralised and “off the shelf” platforms, integrated referral networks, and AI-assisted patient management to support safe, equitable and efficient global delivery.